Related references
Note: Only part of the references are listed.Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
Brigitte Michelsen et al.
ARTHRITIS CARE & RESEARCH (2022)
Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies
Ana-Maria Orbai et al.
RHEUMATOLOGY AND THERAPY (2021)
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study
Philip J. Mease et al.
RMD OPEN (2021)
THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021
L. C. Coates et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
Sara Alonso et al.
FRONTIERS IN MEDICINE (2021)
Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study
Roberta Ramonda et al.
RMD OPEN (2021)
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
Desiree van der Heijde et al.
RHEUMATOLOGY (2020)
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
SECUKINUMAB EFFECTIVENESS IN 1543 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CLINICAL PRACTICE IN 13 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION NETWORK
B. Michelsen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report
Ali Duarte-Garcia et al.
JOURNAL OF RHEUMATOLOGY (2019)
Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database
Kurt R. Oelke et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2019)
Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Population-Based Study
Lihi Eder et al.
ARTHRITIS CARE & RESEARCH (2019)
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
Philip Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
L. C. Coates et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Psoriatic Arthritis
Christopher T. Ritchlin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score
Monika M. Schoels et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part I: Principles of the Management of Spondyloarthritis in Canada
Sherry Rohekar et al.
JOURNAL OF RHEUMATOLOGY (2015)
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics
Philip J. Mease et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
The LUNDEX, a new index of drug efficacy in clinical practice - Results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden
LE Kristensen et al.
ARTHRITIS AND RHEUMATISM (2006)
Share Paper
